Crohn's disease (CD) yields a considerable burden to the Spanish National Health System (NHS). Thanks to the advent of adalimumab and infliximab biosimilars (bADA, bINF), costs burden decreased substantially. However, a further assessment on additional efficiencies is warranted. The NHS’s Willingness to Pay (WTP) per additional Quality Adjusted Life Year (QALY) could be considered an important metric to assess.